Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

New important compounds for targeted and immunotherapies for lung cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.08.18
Views: 167
Rating:

Dr Christian Rolfo - Univeristy of Maryland, Baltimore, USA

Dr Rolfo speaks to ecancer at BEST OF ASCO® 2018 MIAMI SYMPOSIUM about new compounds for targeted therapy and immunotherapy.

These include new compounds found in RET, ALK and ROS.

He also discusses the new compounds in immunotherapy, one specifically, an anti PD-L1 for TGF-β in HBB tumours.

Dr Rolfo finishes on a reminder that we need to test all the patients for driver mutations before starting immunotherapy.

Related videos

follow us

NCRI 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation